GLP-1 mechanism of action research in Canada explores the molecular and physiological biology of glucagon-like peptide-1, one of the most clinically significant incretin hormones. GLP-1 is produced by L-cells in the distal small intestine and colon in response to food ingestion and signals through the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor. Canadian metabolic disease researchers study GLP-1R signalling to understand insulin secretion, glucagon suppression, gastric emptying delay, and hypothalamic appetite regulation.
Pancreatic Beta-Cell Signalling
GLP-1 binding to GLP-1R on pancreatic beta-cells activates adenylyl cyclase, increasing cAMP and activating PKA and EPAC2. This amplifies glucose-stimulated insulin secretion in a glucose-dependent manner — meaning GLP-1 only potentiates insulin release when glucose is elevated. Canadian beta-cell biology researchers study this glucose-dependent mechanism as a safer alternative to non-glucose-dependent insulin secretagogues.
Central Appetite Regulation Research
GLP-1R is expressed in the arcuate nucleus, paraventricular nucleus, and brainstem (area postrema, NTS). GLP-1 and its analogues activate these brain circuits to suppress appetite, reduce food intake, and slow gastric emptying. Canadian appetite biology researchers study GLP-1R signalling in the CNS to understand the neural basis of GLP-1-induced satiety and how synthetic GLP-1 analogues (semaglutide, liraglutide) achieve their weight-reducing effects.
Sourcing GLP-1 Research Compounds in Canada
Research-grade GLP-1 analogues including semaglutide and tirzepatide are available from EhBuddy Peptides in Canada. Lab-tested for purity. For laboratory research use only.
Understanding GLP-1’s multi-organ receptor pharmacology is essential for Canadian researchers working in metabolic disease, obesity biology, and diabetes research.
